# AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

> **NCT00245063** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer

## Interventions

- **DRUG:** cediranib maleate
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacogenomic studies

## Key facts

- **NCT ID:** NCT00245063
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245063, "AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00245063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*